-
Product Insights
NewNet Present Value Model: Foghorn Therapeutics Inc’s FHD-609
Empower your strategies with our Net Present Value Model: Foghorn Therapeutics Inc's FHD-609 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aficamten in Hypertrophic Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aficamten in Hypertrophic Cardiomyopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aficamten in Hypertrophic Cardiomyopathy Drug Details: Aficamten is under development for...
-
Product Insights
Chronic Myelomonocytic Leukemia (CMML) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Myelomonocytic Leukemia (CMML) - Drugs In Development, 2023’, provides an overview of the Chronic Myelomonocytic Leukemia (CMML) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Myelomonocytic Leukemia (CMML), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Synovial Sarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Synovial Sarcoma - Drugs In Development, 2023’, provides an overview of the Synovial Sarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Synovial Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Net Present Value Model: Cardiff Oncology Inc’s Onvansertib Fumarate
Empower your strategies with our Net Present Value Model: Cardiff Oncology Inc's Onvansertib Fumarate report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FHD-286 in Chronic Myelomonocytic Leukemia (CMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FHD-286 in Chronic Myelomonocytic Leukemia (CMML) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.FHD-286 in Chronic Myelomonocytic Leukemia (CMML) Drug Details: FHD-286 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CK-0804 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CK-0804 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:CK-0804 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FHD-286 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FHD-286 in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FHD-286 in Myelodysplastic Syndrome Drug Details: FHD-286 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FHD-286 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FHD-286 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FHD-286 in Refractory Acute Myeloid Leukemia Drug Details: FHD-286 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FHD-286 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FHD-286 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FHD-286 in Relapsed Acute Myeloid Leukemia Drug Details: FHD-286 is...